These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15068865)

  • 1. Reverse transcriptase-based DNA vaccines against drug-resistant HIV-1 tested in a mouse model.
    Isaguliants MG; Zuber B; Boberg A; Sjöstrand D; Belikov SV; Rollman E; Zuber AK; Rechinsky VO; Rytting AS; Källander CF; Hinkula J; Kochetkov SN; Liu M; Wahren B
    Vaccine; 2004 Apr; 22(13-14):1810-9. PubMed ID: 15068865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent cross-reactive immune response against the wild-type and drug-resistant forms of HIV reverse transcriptase after the chimeric gene immunization.
    Starodubova E; Boberg A; Ivanov A; Latyshev O; Petrakova N; Kuzmenko Y; Litvina M; Chernousov A; Kochetkov S; Karpov V; Wahren B; Isaguliants MG
    Vaccine; 2010 Feb; 28(8):1975-86. PubMed ID: 20188253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
    Bazhan SI; Belavin PA; Seregin SV; Danilyuk NK; Babkina IN; Karpenko LI; Nekrasova NA; Lebedev LR; Ignatyev GM; Agafonov AP; Poryvaeva VA; Aborneva IV; Ilyichev AA
    Vaccine; 2004 Apr; 22(13-14):1672-82. PubMed ID: 15068850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice.
    Okazaki T; Terabe M; Catanzaro AT; Pendleton CD; Yarchoan R; Berzofsky JA
    J Virol; 2006 Nov; 80(21):10645-51. PubMed ID: 16920824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
    Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
    Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 reverse transcriptase artificially targeted for proteasomal degradation induces a mixed Th1/Th2-type immune response.
    Starodubova ES; Boberg A; Litvina M; Morozov A; Petrakova NV; Timofeev A; Latyshev O; Tunitskaya V; Wahren B; Isaguliants MG; Karpov VL
    Vaccine; 2008 Sep; 26(40):5170-6. PubMed ID: 18468738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
    Auwerx J; Stevens M; Van Rompay AR; Bird LE; Ren J; De Clercq E; Oberg B; Stammers DK; Karlsson A; Balzarini J
    J Virol; 2004 Jul; 78(14):7427-37. PubMed ID: 15220416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
    Paraschiv S; Otelea D; Baicus C; Tinischi M; Costache M; Neaga E
    Int J Infect Dis; 2009 Jan; 13(1):81-9. PubMed ID: 18632295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations conferring drug resistance affect eukaryotic expression of HIV type 1 reverse transcriptase.
    Isaguliants MG; Belikov SV; Starodubova ES; Gizatullin RZ; Rollman E; Zuber B; Zuber AK; Grishchenko OI; Rytting AS; Källander CF; Kochetkov SN; Karpov VL; Wahren B
    AIDS Res Hum Retroviruses; 2004 Feb; 20(2):191-201. PubMed ID: 15018707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates.
    Rezende LF; Prasad VR
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1716-34. PubMed ID: 15183340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens.
    Bolesta E; Gzyl J; Wierzbicki A; Kmieciak D; Kowalczyk A; Kaneko Y; Srinivasan A; Kozbor D
    Virology; 2005 Feb; 332(2):467-79. PubMed ID: 15680412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.
    Latanova AA; Petkov S; Kilpelainen A; Jansons J; Latyshev OE; Kuzmenko YV; Hinkula J; Abakumov MA; Valuev-Elliston VT; Gomelsky M; Karpov VL; Chiodi F; Wahren B; Logunov DY; Starodubova ES; Isaguliants MG
    Sci Rep; 2018 May; 8(1):8078. PubMed ID: 29799015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A truncated plasmid-encoded HIV-1 reverse transcriptase displays strong immunogenicity.
    Hallengärd D; Wahren B; Bråve A
    Viral Immunol; 2013 Apr; 26(2):163-6. PubMed ID: 23573980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations other than 103N in human immunodeficiency virus type 1 reverse transcriptase (RT) emerge from K103R polymorphism under non-nucleoside RT inhibitor pressure.
    Gatanaga H; Hachiya A; Kimura S; Oka S
    Virology; 2006 Jan; 344(2):354-62. PubMed ID: 16219331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 reverse transcriptase targeted for proteasomal degradation as a prototype vaccine against drug-resistant HIV-1.
    Starodubova E; Boberg A; Kashuba EV; Wahren B; Karpov V; Isaguliants M
    Vaccine; 2006 May; 24(21):4541-7. PubMed ID: 16181708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.
    Parkin NT; Gupta S; Chappey C; Petropoulos CJ
    Antimicrob Agents Chemother; 2006 Jan; 50(1):351-4. PubMed ID: 16377709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.